Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal)

Technology appraisal
Reference number: TA797
Published: 15 June 2022

History

Invitation to participate

Final scope (PDF 185 KB)

Published:

28 April 2021
Final stakeholder list (PDF 184 KB)

Published:

28 April 2021
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 274 KB)

Published:

28 April 2021
Equality impact assessment (Scoping) (PDF 128 KB)

Published:

28 April 2021

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Draft scope post referral (PDF 199 KB)

Published:

28 April 2021
Draft matrix post referral (PDF 184 KB)

Published:

28 April 2021